Disorders of the motor neurone

Published on 10/04/2015 by admin

Filed under Neurology

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1215 times

Disorders of the motor neurone

The motor neurone, or anterior horn cell, lies in the anterior horn of the spinal cord. Its axon extends to the muscle and is the final common pathway for motor output. Disorders of the motor neurone are uncommon.

Motor neurone disease

The most common disease is motor neurone disease (MND), referred to as amyotrophic lateral sclerosis (ALS) or Lou Gehrig’s disease in the USA. The annual incidence is 1 per 100 000 of the population. MND usually affects adults aged over 50 years, the risk increasing with increasing age, but occasionally younger adults may be affected. About 5% of cases may be familial, and in some of these, a genetic abnormality of the enzyme superoxide dismutase (SOD 1, a free radical scavenger) has been identified. The aetiology of the sporadic cases is unknown, but a toxic role has been postulated for the excitatory amino acid neurotransmitter glutamate. Other diseases of the motor neurone are now rare but poliomyelitis was common and its sequelae are still seen.

Clinical features

There are three main patterns of disease (Fig. 1). All are progressive and evolve at different rates. They overlap significantly and in the late stages tend to merge into a diffuse, combined upper motor neurone (UMN) and lower motor neurone (LMN) disorder. The differential diagnosis depends on the pattern of presentation. Sensation must be normal to make the diagnosis. The overall prognosis is poor; death is usually due to respiratory complications from bulbar or respiratory muscle weakness.

Treatment

Treatment is supportive and involves most of the paramedical disciplines: physiotherapy (to optimize function, the best use of walking aids and to advise about positioning); occupational therapy (to optimize the patient’s environment); nursing; and speech therapy (to advise about swallowing and provide communication aids). Psychological support for the patient and relatives is important in a difficult, relentlessly progressive disease. Depression is common and can be treated.

Some drug therapy and other medical interventions are useful. Spasticity can be treated with baclofen. Patients with bulbar involvement may benefit from percutaneous insertion of a gastrostomy tube (percutaneous endoscopic gastrostomy; PEG), which is a simple procedure allowing direct enteral feeding to maintain nutrition and reduce the risk of aspiration pneumonia. PEG feeding also will allow patients who need hydration or parenteral medication to be looked after in most settings, at home or in a hospice rather than a hospital.

Some patients with respiratory weakness but otherwise good function may benefit from nocturnal or diurnal respiratory support. Typically respiratory support will help with symptoms of fatigue and headache, which may not be immediately recognized as symptoms of nocturnal hypoventilation. These are delicate, individual decisions as patients will continue to deteriorate and the respiratory support may prolong an unsatisfactory quality of life. Palliative care services can be very helpful in the managent of this relentlessly progressive condition.

Riluzole, a glutamate antagonist, has been shown to improve 18-month survival by 7%, a small but statistically significant benefit.